{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bacillus+Calmette+Guerin", "query": { "intervention": "Bacillus Calmette Guerin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 153, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bacillus+Calmette+Guerin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T08:51:19.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05126472", "title": "Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "anti-CD40 antibody 2141-V11", "type": "DRUG" }, { "name": "Intravesical Gemcitabine", "type": "DRUG" }, { "name": "Intravesical Gemcitabine with anti-CD40 antibody 2141-V11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-11-08", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05126472" }, { "nct_id": "NCT03335059", "title": "Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Bladder Neoplasm", "Bladder Tumors", "Cancer of Bladder", "Cancer of the Bladder", "Malignant Tumor of Urinary Bladder", "Neoplasms, Bladder", "Urinary Bladder Cancer", "Carcinoma in Situ of Bladder", "Papillary Carcinoma of Bladder (Diagnosis)", "BCG-Unresponsive Bladder Cancer" ], "interventions": [ { "name": "Synergo® RITE + MMC", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Medical Enterprises Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-04-04", "completion_date": "2020-02-26", "has_results": false, "last_update_posted_date": "2020-04-15", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 4, "location_summary": "Hanover, Maryland • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Hanover", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03335059" }, { "nct_id": "NCT03022825", "title": "QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "N-803 and BCG", "type": "DRUG" }, { "name": "N-803", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2017-06-02", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 28, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03022825" }, { "nct_id": "NCT05866536", "title": "Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Type 1 Diabetes", "Diabetes type1", "Autoimmune Diabetes" ], "interventions": [ { "name": "Bacillus Calmette-Guérin", "type": "BIOLOGICAL" }, { "name": "Saline Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2023-05-04", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Charlestown, Massachusetts", "locations": [ { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05866536" }, { "nct_id": "NCT05768347", "title": "Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Non-Invasive Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-08-10", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768347" }, { "nct_id": "NCT03258593", "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Vicineum", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Bladder Biopsy", "type": "PROCEDURE" }, { "name": "TURBT", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Urine cytology", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-06-07", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258593" }, { "nct_id": "NCT03552796", "title": "sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Bladder Carcinoma", "Bladder Cancer Stage 0", "Bladder Cancer Stage I" ], "interventions": [ { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2023-08-01", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552796" }, { "nct_id": "NCT00003759", "title": "AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "BCG vaccine", "type": "BIOLOGICAL" }, { "name": "valrubicin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Anthra Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003759" }, { "nct_id": "NCT07048496", "title": "Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "BCG delivery at home", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-07-05", "completion_date": "2026-09-05", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07048496" }, { "nct_id": "NCT00006034", "title": "Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Intracel", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-09-20T08:51:19.300Z", "location_count": 1, "location_summary": "Frederick, Maryland", "locations": [ { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006034" } ] }